Tirzepatide

Tirzepatide is a dual GIP and GLP-1 receptor agonist — a next-generation weight loss peptide that targets two metabolic pathways simultaneously. Originally developed as Mounjaro for diabetes, it has emerged as one of the most powerful fat loss agents available, producing significantly greater results than GLP-1-only medications like Semaglutide.

Clinical trials show an average weight loss of 20–22% of total body weight over 72 weeks. Patients commonly report reduced appetite, improved blood sugar regulation, increased energy, and significant body composition changes within the first 4–8 weeks of treatment.

Tirzepatide is administered via a once-weekly subcutaneous injection, typically in the abdomen, thigh, or upper arm. Your protocol will include a gradual dose escalation to minimize side effects and optimize results.

The most common side effects are gastrointestinal — nausea, mild bloating, or reduced appetite — and typically occur during dose escalation. These generally subside as your body adjusts. Our medical team monitors your progress throughout to ensure a safe and comfortable experience.

Tirzepatide is ideal for adults looking to achieve significant, sustained fat loss — particularly those who have struggled with diet and exercise alone, have metabolic concerns, or are seeking a medically supervised body transformation. A health assessment is required to confirm eligibility.